Wednesday, April 12, 2023 12:55:56 PM
Sanofi stops Antabuse.
Again one drug gone that emphases' even more the 'unmet need' for something that works.
ADIL should speed up things.
AIMO
Again one drug gone that emphases' even more the 'unmet need' for something that works.
ADIL should speed up things.
AIMO
All In My Opinion. I am not advising anything, nor accusing anyone.
Recent ADIL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 12:40:53 PM
- Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2026 08:21:54 PM
- Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045 • GlobeNewswire Inc. • 04/29/2026 01:07:00 PM
- Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program • GlobeNewswire Inc. • 04/27/2026 12:47:00 PM
- Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial • GlobeNewswire Inc. • 04/22/2026 01:35:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2026 09:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2026 09:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 09:00:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2026 09:00:04 PM
- Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans • GlobeNewswire Inc. • 03/24/2026 01:07:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 01:15:35 PM
- Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/06/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2026 10:03:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 01:17:24 PM
- Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement • GlobeNewswire Inc. • 03/03/2026 01:17:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/24/2026 02:06:05 PM
- Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement • GlobeNewswire Inc. • 02/24/2026 02:00:00 PM
- Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One • GlobeNewswire Inc. • 02/23/2026 01:30:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/18/2026 04:06:49 PM
- Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/17/2026 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/04/2026 09:30:34 PM
- Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04 • GlobeNewswire Inc. • 02/04/2026 02:35:00 PM
